- By ICR Secretariat
- Posted Wednesday, January 13, 2021
CRUK Scientists develop drug that targets KRAS pathways
http://www.pharmatimes.com/news/cruk_scientists_develop_drug_that_targets_kras_pathways_1360681
A new study, funded by Cancer Research UK (CRUK) and Wellcome, has discovered a new way to target the KRAS mutation, which is found in a number of hard-to-treat cancer types.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- Valneva partners with Oxford Immunotec on T cell analysis for COVID-19 vaccine 19/01/2021 03:03 PM
- UK says vaccine manufacturing is 'lumpy' but still on course for targets 19/01/2021 03:01 PM
- UK hopes to ease lockdown from March: minister 19/01/2021 02:59 PM
Useful Links
Contact Us
Suite 10, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org